Pharmaceuticals
Pharma - Formulators
Rubicon Research delivered its fourth consecutive earnings surprise since its IPO with strong revenue, EBITDA, and PAT beats, driven by stellar execution and compliance credentials.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
